Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (Zavegepant) Intranasal (IN) for the Acute Treatment of Migraine

Next Previous
Trial Profile

A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (Zavegepant) Intranasal (IN) for the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zavegepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors Biohaven Pharmaceuticals; Pfizer

Most Recent Events

  • 18 Apr 2024 Results presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 27 Apr 2023 Results of subgroup analysis (n=603) assessing the effects of concomitant use of CGRP monoclonal antibodies on the safety and tolerability of zavegepant nasal spray in the acute treatment of migraine, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 27 Apr 2023 Results (n=603 ) for safety and tolerability of zavegepant 10 mg nasal spray in the acute treatment of migraine, presented at the 75th Annual Meeting of the American Academy of Neurology 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top